Abstract
A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes
Current Drug Safety
Title:Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure
Volume: 7 Issue: 5
Author(s): Sohail Qayyum, Huijun Dong, Dianne Kovacic, Sidra Sohail, Bradford Waters, Camille Thornton and Cathy E. Corbett
Affiliation:
Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes
Abstract: A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Export Options
About this article
Cite this article as:
Qayyum Sohail, Dong Huijun, Kovacic Dianne, Sohail Sidra, Waters Bradford, Thornton Camille and E. Corbett Cathy, Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050013
DOI https://dx.doi.org/10.2174/1574886311207050013 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Magnetic Nanoparticles Utilized in Hemodialysis for the Treatment of Hyperhomocysteinemia:The New Challenge of Nanobiotechnology
Current Nanoscience From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Use of Antipsychotics and Breastfeeding
Current Women`s Health Reviews Vitamin D Increases Aβ140 Plasma Levels and Protects Lymphocytes from Oxidative Death in Mild Cognitive Impairment Patients
Current Alzheimer Research Review of Treatment for Cocaine Dependence
Current Drug Abuse Reviews Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Current Topics in Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Nociceptin/Orphanin FQ Peptide Receptor as a Therapeutic Target for Obesity
Mini-Reviews in Medicinal Chemistry Alzheimer’s Drug Discovery Maze: A Snap View of the Past Decade’s Diverse Pharmacological Targets for the Disorder
Mini-Reviews in Medicinal Chemistry KF/Clinoptilolite Nanoparticles as a Heterogeneous Catalyst for Green Synthesis of pyrido[2,1-a]isoquinolines using Four-Component Reaction of Alkyl Bromides
Combinatorial Chemistry & High Throughput Screening Commentary Research Highlights: Untangling Alzheimer Disease Pathology
CNS & Neurological Disorders - Drug Targets Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection
Infectious Disorders - Drug Targets Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Idarucizumab: What Should We Know?
Current Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design Towards a Unifying Hypothesis of Alzheimers Disease: Cholinergic System Linked to Plaques, Tangles and Neuroinflammation
Current Medicinal Chemistry Treatment of Patients with Schizophrenia and Substance Abuse Disorders
Current Pharmaceutical Design